Detalles de la búsqueda
1.
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Mult Scler
; 29(2): 221-235, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36433775
2.
Desirability and acceptability of a treatment-sequencing model in relapsing-remitting multiple sclerosis: A health technology assessment perspective.
Int J Technol Assess Health Care
; 36(2): 162-166, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32423521
3.
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
Value Health
; 22(7): 772-776, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31277823
4.
Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data.
Value Health
; 22(1): 77-84, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30661637
5.
Surgical Resection Preferences and Perceptions among Medical Oncologists Treating Liver Metastases from Colorectal Cancer.
Ann Surg Oncol
; 23(2): 375-81, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26561404
6.
Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
Mult Scler Relat Disord
; 79: 105052, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37832254
7.
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Neurodegener Dis Manag
; 13(4): 215-221, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37287269
8.
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
Neurodegener Dis Manag
; 12(6): 285-293, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35920065
9.
An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing-Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach.
Adv Ther
; 39(2): 892-908, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34796464
10.
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment.
Curr Med Res Opin
; 37(3): 459-464, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33331183
11.
Creating a Real-World Data, United States Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression.
Adv Ther
; 38(9): 4786-4797, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34333756
12.
Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis.
Adv Ther
; 37(9): 3791-3806, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32647909
13.
Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review.
Curr Med Res Opin
; 36(5): 809-826, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32129684
14.
Patients With High-disease-activity Relapsing-Remitting Multiple Sclerosis in Real-world Clinical Practice: A Population-based Study in Sweden.
Clin Ther
; 42(2): 240-250, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31899001
15.
Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis.
J Med Econ
; 23(5): 474-483, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31903813
16.
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
Adv Ther
; 37(1): 225-239, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31701485
17.
Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.
Med Decis Making
; 40(2): 198-211, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32065023
18.
Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Curr Med Res Opin
; 35(8): 1371-1378, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30786783
19.
Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
J Med Econ
; 21(7): 676-686, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29618273
20.
Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Curr Med Res Opin
; 34(8): 1361-1371, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29149804